Maverick Therapeutics

Maverick Therapeutics is a biotechnology company dedicated to improving the lives of patients with solid tumors, focusing on the deep integration of expertise in drug development to design and deliver groundbreaking immunotherapy platforms. Our highly innovative COBRA™ platform is the most advanced and conditionally active bispecific T-cell engagement platform in its class, designed to safely target solid tumors with high specificity and potent activity while limiting on-target toxicity in normal tissues. Maverick Therapeutics was founded in 2016 and is led by a team of leading experts in protein engineering and T-cell therapy research and development. Our team consists of individuals from incredibly diverse backgrounds who share a common passion for developing safe and effective treatments for a wide range of solid tumor patients. Each member brings their unique personality and professional experience, forming a complete discovery and development team. Our approach is to first focus on the needs of the patient population and then reverse-engineer technologies that can deliver solutions.